Loading...
Header Logo
Keywords
Last Name
Institution

BETTY LAMOTHE

TitleAssistant Professor
InstitutionMD Anderson
DepartmentExperimental Therapeutics
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Abou Dalle I, Cortes JE, Pinnamaneni P, Lamothe B, Diaz Duque A, Randhawa J, Pemmaraju N, Jabbour E, Ferrajoli A, Wierda WG, Estrov Z, Konopleva M, Ravandi F, Alvarado Y, Borthakur G, Gandhi V, Kantarjian HM. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia. Acta Haematol. 2018; 140(1):30-39. PMID: 30071517.
      View in: PubMed
    2. Lamothe B, Wierda WG, Keating MJ, Gandhi V. Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses. Clin Cancer Res. 2016 Sep 15; 22(18):4712-26. PMID: 27026200.
      View in: PubMed
    3. Cervantes-Gomez F, Lamothe B, Woyach JA, Wierda WG, Keating MJ, Balakrishnan K, Gandhi V. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2015 Aug 15; 21(16):3705-15. PMID: 25829398.
      View in: PubMed
    4. Lamothe B, Cervantes-Gomez F, Sivina M, Wierda WG, Keating MJ, Gandhi V. Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia. Blood. 2015 Jan 08; 125(2):407-10. PMID: 25573971.
      View in: PubMed
    5. Lamothe B, Lai Y, Hur L, Orozco NM, Wang J, Campos AD, Xie M, Schneider MD, Lockworth CR, Jakacky J, Tran D, Ho M, Dawud S, Dong C, Lin HK, Hu P, Estrov Z, Bueso-Ramos CE, Darnay BG. Deletion of TAK1 in the myeloid lineage results in the spontaneous development of myelomonocytic leukemia in mice. PLoS One. 2012; 7(12):e51228. PMID: 23251462.
      View in: PubMed
    6. Lamothe B, Lai Y, Xie M, Schneider MD, Darnay BG. TAK1 is essential for osteoclast differentiation and is an important modulator of cell death by apoptosis and necroptosis. Mol Cell Biol. 2013 Feb; 33(3):582-95. PMID: 23166301.
      View in: PubMed
    7. Wu CY, Kang HY, Yang WL, Wu J, Jeong YS, Wang J, Chan CH, Lee SW, Zhang X, Lamothe B, Campos AD, Darnay BG, Lin HK. Critical role of monoubiquitination of histone H2AX protein in histone H2AX phosphorylation and DNA damage response. J Biol Chem. 2011 Sep 02; 286(35):30806-15. PMID: 21690091.
      View in: PubMed
    8. Yin Q, Lamothe B, Darnay BG, Wu H. Structural basis for the lack of E2 interaction in the RING domain of TRAF2. Biochemistry. 2009 Nov 10; 48(44):10558-67. PMID: 19810754.
      View in: PubMed
    9. Yang WL, Wang J, Chan CH, Lee SW, Campos AD, Lamothe B, Hur L, Grabiner BC, Lin X, Darnay BG, Lin HK. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science. 2009 Aug 28; 325(5944):1134-8. PMID: 19713527.
      View in: PubMed
    10. Yin Q, Lin SC, Lamothe B, Lu M, Lo YC, Hura G, Zheng L, Rich RL, Campos AD, Myszka DG, Lenardo MJ, Darnay BG, Wu H. E2 interaction and dimerization in the crystal structure of TRAF6. Nat Struct Mol Biol. 2009 Jun; 16(6):658-66. PMID: 19465916.
      View in: PubMed
    11. Lamothe B, Campos AD, Webster WK, Gopinathan A, Hur L, Darnay BG. The RING domain and first zinc finger of TRAF6 coordinate signaling by interleukin-1, lipopolysaccharide, and RANKL. J Biol Chem. 2008 Sep 05; 283(36):24871-80. PMID: 18617513.
      View in: PubMed
    12. Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG, Darnay BG, Lamothe B, Sun H, Talpaz M, Donato NJ. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst. 2008 Jul 02; 100(13):926-39. PMID: 18577747.
      View in: PubMed
    13. Lin SC, Chung JY, Lamothe B, Rajashankar K, Lu M, Lo YC, Lam AY, Darnay BG, Wu H. Molecular basis for the unique deubiquitinating activity of the NF-kappaB inhibitor A20. J Mol Biol. 2008 Feb 15; 376(2):526-40. PMID: 18164316.
      View in: PubMed
    14. Lamothe B, Webster WK, Gopinathan A, Besse A, Campos AD, Darnay BG. TRAF6 ubiquitin ligase is essential for RANKL signaling and osteoclast differentiation. Biochem Biophys Res Commun. 2007 Aug 10; 359(4):1044-9. PMID: 17572386.
      View in: PubMed
    15. Darnay BG, Besse A, Poblenz AT, Lamothe B, Jacoby JJ. TRAFs in RANK signaling. Adv Exp Med Biol. 2007; 597:152-9. PMID: 17633024.
      View in: PubMed
    16. Besse A, Lamothe B, Campos AD, Webster WK, Maddineni U, Lin SC, Wu H, Darnay BG. TAK1-dependent signaling requires functional interaction with TAB2/TAB3. J Biol Chem. 2007 Feb 09; 282(6):3918-28. PMID: 17158449.
      View in: PubMed
    17. Lamothe B, Besse A, Campos AD, Webster WK, Wu H, Darnay BG. Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of I kappa B kinase activation. J Biol Chem. 2007 Feb 09; 282(6):4102-12. PMID: 17135271.
      View in: PubMed
    18. Mattoon DR, Lamothe B, Lax I, Schlessinger J. The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway. BMC Biol. 2004 Nov 18; 2:24. PMID: 15550174.
      View in: PubMed
    19. Lamothe B, Yamada M, Schaeper U, Birchmeier W, Lax I, Schlessinger J. The docking protein Gab1 is an essential component of an indirect mechanism for fibroblast growth factor stimulation of the phosphatidylinositol 3-kinase/Akt antiapoptotic pathway. Mol Cell Biol. 2004 Jul; 24(13):5657-66. PMID: 15199124.
      View in: PubMed
    20. Baudry A, Jackerott M, Lamothe B, Kozyrev SV, Leroux L, Durel B, Saint-Just S, Joshi RL. Partial rescue of insulin receptor-deficient mice by transgenic complementation with an activated insulin receptor in the liver. Gene. 2002 Oct 16; 299(1-2):219-25. PMID: 12459269.
      View in: PubMed
    21. Lax I, Wong A, Lamothe B, Lee A, Frost A, Hawes J, Schlessinger J. The docking protein FRS2alpha controls a MAP kinase-mediated negative feedback mechanism for signaling by FGF receptors. Mol Cell. 2002 Oct; 10(4):709-19. PMID: 12419216.
      View in: PubMed
    22. Ye H, Arron JR, Lamothe B, Cirilli M, Kobayashi T, Shevde NK, Segal D, Dzivenu OK, Vologodskaia M, Yim M, Du K, Singh S, Pike JW, Darnay BG, Choi Y, Wu H. Distinct molecular mechanism for initiating TRAF6 signalling. Nature. 2002 Jul 25; 418(6896):443-7. PMID: 12140561.
      View in: PubMed
    23. Mukhopadhyay A, Shishodia S, Suttles J, Brittingham K, Lamothe B, Nimmanapalli R, Bhalla KN, Aggarwal BB. Ectopic expression of protein-tyrosine kinase Bcr-Abl suppresses tumor necrosis factor (TNF)-induced NF-kappa B activation and IkappaBalpha phosphorylation. Relationship with down-regulation of TNF receptors. J Biol Chem. 2002 Aug 23; 277(34):30622-8. PMID: 12060665.
      View in: PubMed
    24. Wong A, Lamothe B, Lee A, Schlessinger J, Lax I, Li A. FRS2 alpha attenuates FGF receptor signaling by Grb2-mediated recruitment of the ubiquitin ligase Cbl. Proc Natl Acad Sci U S A. 2002 May 14; 99(10):6684-9. PMID: 11997436.
      View in: PubMed
    25. Majumdar S, Lamothe B, Aggarwal BB. Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. J Immunol. 2002 Mar 15; 168(6):2644-51. PMID: 11884428.
      View in: PubMed
    26. Lamothe B, Aggarwal BB. Ectopic expression of Bcl-2 and Bcl-xL inhibits apoptosis induced by TNF-related apoptosis-inducing ligand (TRAIL) through suppression of caspases-8, 7, and 3 and BID cleavage in human acute myelogenous leukemia cell line HL-60. J Interferon Cytokine Res. 2002 Feb; 22(2):269-79. PMID: 11911810.
      View in: PubMed
    27. Jackerott M, Baudry A, Lamothe B, Bucchini D, Jami J, Joshi RL. Endocrine pancreas in insulin receptor-deficient mouse pups. Diabetes. 2001 Feb; 50 Suppl 1:S146-9. PMID: 11272177.
      View in: PubMed
    28. Baudry A, Lamothe B, Bucchini D, Jami J, Montarras D, Pinset C, Joshi RL. IGF-1 receptor as an alternative receptor for metabolic signaling in insulin receptor-deficient muscle cells. FEBS Lett. 2001 Jan 19; 488(3):174-8. PMID: 11163767.
      View in: PubMed
    29. Lamothe B, Joshi S. Current developments and future prospects for HIV gene therapy using interfering RNA-based strategies. Front Biosci. 2000 May 01; 5:D527-55. PMID: 10799355.
      View in: PubMed
    30. Baudry A, Bucchini D, Deltour L, Desbois P, Durel B, Duvillié B, Jackerott M, Jami J, Joshi RL, Lamothe B, Lamotte L, Cordonnier-Lefort N, Leroux L, Saint Just S. [Insulin and its receptor: lessons learned from the disruption of their gene in mice]. Journ Annu Diabetol Hotel Dieu. 1999; 105-13. PMID: 10732410.
      View in: PubMed
    31. Lamothe B, Baudry A, Desbois P, Lamotte L, Bucchini D, De Meyts P, Joshi RL. Genetic engineering in mice: impact on insulin signalling and action. Biochem J. 1998 Oct 15; 335 ( Pt 2):193-204. PMID: 9761714.
      View in: PubMed
    32. Lamothe B, Duvillié B, Cordonnier N, Baudry A, Saint-Just S, Bucchini D, Jami J, Joshi RL. Genetic manipulation of insulin action and beta-cell function in mice. Mol Cell Biochem. 1998 May; 182(1-2):161-8. PMID: 9609125.
      View in: PubMed
    33. Lamothe B, Baudry A, Christoffersen CT, De Meyts P, Jami J, Bucchini D, Joshi RL. Insulin receptor-deficient cells as a new tool for dissecting complex interplay in insulin and insulin-like growth factors. FEBS Lett. 1998 Apr 24; 426(3):381-5. PMID: 9600271.
      View in: PubMed
    34. Joshi RL, Lamothe B, Bucchini D, Jami J. Genetically engineered mice as animal models for NIDDM. FEBS Lett. 1997 Jan 20; 401(2-3):99-103. PMID: 9013866.
      View in: PubMed
    35. Lamothe B, Bucchini D, Jami J, Joshi RL. Reexamining interaction of the SH2 domains of SYP and GAP with insulin and IGF-1 receptors in the two-hybrid system. Gene. 1996 Dec 05; 182(1-2):77-80. PMID: 8982070.
      View in: PubMed
    36. Joshi RL, Lamothe B, Cordonnier N, Mesbah K, Monthioux E, Jami J, Bucchini D. Targeted disruption of the insulin receptor gene in the mouse results in neonatal lethality. EMBO J. 1996 Apr 01; 15(7):1542-7. PMID: 8612577.
      View in: PubMed
    37. Lamothe B, Bucchini D, Jami J, Joshi RL. Interaction of p85 subunit of PI 3-kinase with insulin and IGF-1 receptors analysed by using the two-hybrid system. FEBS Lett. 1995 Oct 02; 373(1):51-5. PMID: 7589433.
      View in: PubMed
    38. Erratum. Proceedings of the National Academy of Sciences of the United States of America. 99:10941.
    39. Carfilzomib triggers cell death in chronic lymphocytic leukemia by inducing proapoptotic and endoplasmic reticulum stress responses. Clinical Cancer Research. 22:4712-4726.
    40. TRAFs in RANK signaling. Advances in Experimental Medicine and Biology. 597:152-159.
    41. Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia. Clinical Cancer Research. 21:3705-3715.
    LAMOTHE's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description